Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 9, 2017
- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data in AGS-004 Program for the Treatment of HIV - ...
Jul 26, 2017
DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced immunogenicity data from a stud...
Jun 22, 2017
DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the closing o...
Jun 16, 2017
DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that it entered ...
May 10, 2017
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today provided an update on the ADAPT trial, a r...
Apr 18, 2017
DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its random...
Feb 22, 2017
-Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the A...
Feb 13, 2017
DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the comp...
Feb 6, 2017
DURHAM, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the company...
Jan 19, 2017
DURHAM, N.C., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today the completion ...
Dec 14, 2016
DURHAM, N.C., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today that it...
Dec 13, 2016
DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of...
Dec 7, 2016
DURHAM, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported highlights from t...
Dec 1, 2016
DURHAM, N.C., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that registration is open for the company'...
Nov 29, 2016
DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presenting at the E...
Page:
...
Next Last
 
= add release to Briefcase

Stock Quote

NASDAQ: ARGS
0.20
- 0.02 (-6.98%)

Day High:
0.21

Day Low:
0.18

Volume:
913,240

11:05 AM ET on Aug 17, 2017
Delayed at least 20 minutes.

Tweets